IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 56.778
AS - Asia 9.162
EU - Europa 6.627
SA - Sud America 1.263
Continente sconosciuto - Info sul continente non disponibili 715
AF - Africa 92
OC - Oceania 40
Totale 74.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 56.480
SG - Singapore 3.991
CN - Cina 2.105
BR - Brasile 1.049
UA - Ucraina 977
RU - Federazione Russa 939
IT - Italia 933
HK - Hong Kong 862
IE - Irlanda 768
DE - Germania 686
VN - Vietnam 653
FR - Francia 558
KR - Corea 556
PL - Polonia 434
GB - Regno Unito 412
FI - Finlandia 361
BD - Bangladesh 265
JP - Giappone 228
SE - Svezia 209
CA - Canada 177
NL - Olanda 134
IN - India 98
ID - Indonesia 74
AR - Argentina 66
MX - Messico 52
IQ - Iraq 48
ES - Italia 46
AT - Austria 35
EC - Ecuador 30
MY - Malesia 30
CO - Colombia 29
PK - Pakistan 29
AU - Australia 28
BE - Belgio 27
CL - Cile 26
TR - Turchia 26
UZ - Uzbekistan 25
PH - Filippine 24
ZA - Sudafrica 24
PE - Perù 19
EG - Egitto 18
IL - Israele 18
TH - Thailandia 18
MA - Marocco 17
SA - Arabia Saudita 17
VE - Venezuela 17
A2 - ???statistics.table.value.countryCode.A2??? 15
PY - Paraguay 15
PT - Portogallo 14
AE - Emirati Arabi Uniti 13
CR - Costa Rica 13
EU - Europa 12
GR - Grecia 12
JO - Giordania 12
NZ - Nuova Zelanda 12
CH - Svizzera 9
IR - Iran 9
JM - Giamaica 9
TW - Taiwan 9
NP - Nepal 8
RO - Romania 8
CZ - Repubblica Ceca 7
KE - Kenya 7
LT - Lituania 7
TT - Trinidad e Tobago 7
AL - Albania 6
AZ - Azerbaigian 6
ET - Etiopia 6
KZ - Kazakistan 6
NO - Norvegia 6
SV - El Salvador 6
BO - Bolivia 5
DK - Danimarca 5
DZ - Algeria 5
GT - Guatemala 5
HU - Ungheria 5
MK - Macedonia 5
PA - Panama 5
PR - Porto Rico 5
TN - Tunisia 5
UY - Uruguay 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
HN - Honduras 4
KH - Cambogia 4
LB - Libano 4
MD - Moldavia 4
NI - Nicaragua 4
RS - Serbia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
LK - Sri Lanka 3
LV - Lettonia 3
OM - Oman 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
BW - Botswana 2
CI - Costa d'Avorio 2
Totale 73.965
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.542
Houston 12.275
Fairfield 2.728
Singapore 2.002
Ann Arbor 1.724
Ashburn 1.697
Seattle 1.161
San Jose 1.002
Chandler 910
Cambridge 889
Hong Kong 853
Jacksonville 837
Dublin 687
Beijing 622
Medford 531
Dearborn 461
Hangzhou 424
Kraków 403
Santa Clara 377
New York 340
Council Bluffs 299
The Dalles 269
Los Angeles 261
Ho Chi Minh City 242
Lawrence 238
Rome 206
Tokyo 190
Dallas 174
Lauterbourg 169
Zhengzhou 164
Hanoi 156
Helsinki 153
Buffalo 151
San Diego 141
Moscow 127
Menlo Park 120
Chicago 100
Milan 88
São Paulo 85
Mülheim 83
Colorado Springs 76
Naples 73
Monte Vista 57
Redwood City 57
London 56
Norwalk 55
Toronto 53
Shanghai 49
Cardiff 47
Boardman 46
Columbus 46
Mountain View 46
Phoenix 46
Redondo Beach 45
San Francisco 45
Brooklyn 44
Montreal 43
Detroit 42
Jakarta 42
Verona 42
Guangzhou 40
Denver 39
Hefei 39
Orem 38
Atlanta 37
San Mateo 37
Nanjing 34
Rio de Janeiro 32
University Park 31
Belo Horizonte 29
Nuremberg 28
Palo Alto 28
Falls Church 27
Kunming 27
Warsaw 27
Brussels 25
Da Nang 25
Munich 25
Stockholm 25
Frankfurt am Main 24
Jinan 22
Saint Petersburg 22
Chennai 21
Boston 20
Tashkent 20
Haiphong 19
Brasília 18
Mexico City 18
Amsterdam 17
Curitiba 17
Manchester 17
Poplar 17
Redmond 17
Washington 17
Charlotte 16
Zaltbommel 16
Kuala Lumpur 15
Philadelphia 15
Baghdad 14
Totale 60.629
Salva come PNG Salva come JPEG
Nome #
β2-Agonist Therapy in Lung Disease 552
An update on the pharmacotherapeutic management of lower respiratory tract infections 530
A systems medicine clinical platform for understanding and managing non- communicable diseases 518
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 516
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 510
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 509
Interaction between corticosteroids and muscarinic antagonists in human airways 505
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 502
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 491
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 490
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 489
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 487
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 486
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 485
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 485
Asthma and comorbid medical illness. 484
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 484
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 483
Optimizing drug delivery in COPD: The role of inhaler devices 483
Airflow obstruction: Is it asthma or is it COPD? 481
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 479
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 475
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 472
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 468
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 465
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 465
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 461
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 461
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 457
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 453
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 451
Umeclidinium for the treatment of chronic obstructive pulmonary disease 451
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 449
Metabolic syndrome and risk of pulmonary involvement 447
The prevalence of asthma and COPD in Italy: a practice-based study 447
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 447
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 447
Tiotropium formulations and safety: a network meta-analysis 446
Asthma and comorbid medical illness 441
Role of muscarinic antagonists in asthma therapy 440
Bronchodilator therapy for chronic cough 440
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 439
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 439
Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review 439
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis 436
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 435
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 435
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 434
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 432
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 432
New Treatments for COPD in the Elderly 431
The Challenges of Precision Medicine in COPD 431
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 431
The effect of indacaterol during an acute exacerbation of COPD 428
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 428
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 427
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 425
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 424
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 423
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 422
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 422
Translational study searching for synergy between glycopyrronium and indacaterol 421
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 420
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 420
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 419
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 419
Comorbidities of asthma 418
Biomarkers of lung damage associated with tobacco smoke in induced sputum 417
Adherence to COPD treatment: Myth and reality 417
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 415
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 415
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 415
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 415
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 410
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 409
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 405
Treating systemic effects of COPD 403
Influence of ethnicity on response to asthma drugs 403
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 402
Indacaterol for the treatment of chronic obstructive pulmonary disease 399
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 397
The clinical use of regenerative therapy in COPD 392
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 391
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 390
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 390
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 389
Cardiovascular disease in patients with COPD 385
Diabetes mellitus among outpatients with COPD attending a university hospital. 377
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 377
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 374
COPD diagnosis by a gas sensor array 369
Biomarkers in COPD 368
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 368
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome? 367
An update on bronchodilators in Phase I and II clinical trials 362
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 362
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 362
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 361
Brain natriuretic peptide: Much more than a biomarker 361
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 361
Totale 43.490
Salva come PNG Salva come JPEG
Categoria #
all - tutte 200.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 200.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.165 0 225 72 55 77 259 145 109 133 271 159 660
2022/20232.677 348 150 54 319 239 662 248 172 235 19 161 70
2023/2024889 192 27 68 11 85 212 61 38 16 34 12 133
2024/20255.845 217 1.349 622 318 184 206 510 321 538 548 565 467
2025/20269.902 649 503 1.208 739 889 317 1.273 1.156 1.385 713 617 453
2026/20271.233 1.031 202 0 0 0 0 0 0 0 0 0 0
Totale 74.677